InvestorsHub Logo
Followers 19
Posts 817
Boards Moderated 0
Alias Born 12/12/2016

Re: TTTav66 post# 213667

Wednesday, 10/09/2019 7:48:26 AM

Wednesday, October 09, 2019 7:48:26 AM

Post# of 462654
A friendly reminder for the regulators & decision makers?

“Alzheimer's disease is a progressive, irreversible neurological disease and the most common cause of dementia. In the U.S., there are over five million individuals living with Alzheimer's disease and an estimated 50 million people live with dementia worldwide. Today, there are no commercially available therapies to address the underlying cause of Alzheimer's. According to the World Alzheimer Report 2019, the current annual cost of dementia is estimated at $1 trillion, a figure set to double by 2030.1”

https://www.globenewswire.com/news-release/2019/10/09/1927217/0/en/Anavex-Life-Sciences-Announces-ATTENTION-AD-ANAVEX-2-73-Extension-Clinical-Study-in-Early-Alzheimer-s-Disease.html
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News